A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)
Clinical trial NCT05939596 · UNKNOWN
Trial details
- NCT number
- NCT05939596
- Sponsor
- AIM Vaccine Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-10
- Primary completion
- 2023-09-28
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.